1887

Journal of General Virology header logo

Volume 77, Issue 8

Human antibodies that neutralize primary human immunodeficiency virus type 1 do not provide protection in an model Free

Abstract

Recently, conflicting data have been published about the ability of antibodies which efficiently neutralize T cell-adapted human immunodeficiency virus type 1 (HIV-1) strains to neutralize primary HIV-1 strains and . Here we present data indicating that such antibodies fail to neutralize primary HIV-1 strains . To this end, a newly developed chimeric human-to-mouse model was used, in which several aspects of primary HIV-1 infection are mimicked. Poly- and monoclonal anti-bodies protected the grafted human cells, in a dose-dependent way, from infection with T cell-adapted HIV-1 in this system. A human monoclonal antibody specific for the CD4 binding domain that efficiently neutralizes HIV-1 IIIB did not protect the human graft from HIV-1 IIIB infection. None of the antibodies provided protection in the model against infection with primary HIV-1 strains, although they were able to neutralize these same strains .

  • Received:
  • Accepted:
  • Published Online:
© Journal of General Virology 1996
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-8-1667
1996-08-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/8/JV0770081667.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-8-1667&mimeType=html&fmt=ahah

References

  1. Back N. K., Smit L., Schutten M., Nara P. L., Tersmette M., Goudsmit J. 1993; Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. Journal of Virology 67:6897–6902
     [Google Scholar]
  2. Back N. K., Smit L., de Jong J. J., Keulen W., Schutten M., Goudsmit J., Tersmette M. 1994; An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199:431–438
     [Google Scholar]
  3. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. 1994; Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology 68:6006–6013
     [Google Scholar]
  4. Broliden P. A., von Gegerfelt A., Clapham P., Rosen J., Fenyo E. M., Wahren B., Broliden K. 1992; Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proceedings of the National Academy of Sciences, USA 89:461–465
     [Google Scholar]
  5. Embretson J., Zupancic M., Ribas J. L., Burke A., Racz P., Tenner-Racz K., Haase A. T. 1993; Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS [see comments]. Nature 362:359–362
     [Google Scholar]
  6. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Others 1992; Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728–730
     [Google Scholar]
  7. Gallo R. C., Sarin P. S., Gelmann E. P., Robert-Guroff M., Richardson E., Kalyanaraman V. S., Mann D., Sidhu G. D., Stahl R. E., Zolla-Pazner S., Leibowitch J., Popovic M. 1983; Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865–867
     [Google Scholar]
  8. Gartner S., Popovic M. 1990; Macrophage tropism of HIV-1. AIDS Research and Human Retroviruses 6:1017–1021
     [Google Scholar]
  9. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. 1986; The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215–219
     [Google Scholar]
  10. Gorny M. K., Xu J. Y., Karwowska S., Buchbinder A., Zolla-Pazner S. 1993; Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. Journal of Immunology 150:635–643
     [Google Scholar]
  11. Groenink M., Moore J. P., Broersen S., Schuitemaker H. 1995; Equal levels of gp!20 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. Journal of Virology 69:523–527
     [Google Scholar]
  12. Hinkula J., Bratt G., Gilljam G., Nordiund S., Broliden P. A., Holmberg V., Olausson-Hansson E., Albert J., Sandstrom E., Wahren B. 1994; Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. Journal of Acquired Immune Deficiency Syndromes 7:940–951
     [Google Scholar]
  13. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. 1995; Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [see comments]. Nature 373:123–126
     [Google Scholar]
  14. Huppes W., de Geus B., Zurcher C., Van Bekkum D. W. 1992; Acute human vs. mouse graft vs. host disease in normal and immuno-deficient mice. European Journal of Immunology 22:197–206
     [Google Scholar]
  15. Huppes W., Paulonis J., Dijk H., Van Rooijen N., Van Bekkum D. W. 1993; The role of natural antibodies and ABO (H) blood groups in transplantation of human lymphoid cells into mice. European Journal of Immunology 23:26–32
     [Google Scholar]
  16. Huppes W., Fickenscher H., ’tHart B. A., Fleckenstein B. 1994; Cytokine dependence of human to mouse graft-versus-host disease. Scandinavian Journal of Immunology 40:26–36
     [Google Scholar]
  17. Jansen R. W., Schols D., Pauwels R., de Clercq E., Meijer D. K. F. 1993; Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Molecular Pharmacology 44:1003–1007
     [Google Scholar]
  18. Kuipers M. E., Swart P. J., Schutten M., Smit C., Proost J. H., Osterhaus A. D. M. E., Meijer D. K. F. 1996; Pharmacokinetics and anti-HIV-1 efficacy of negatively charged human serum albumins in mice.. Antiviral Research (in press)
    [Google Scholar]
  19. McCune J. M., Namikawa R., Shih C. C., Rabin L., Kaneshima H. 1990; Suppression of HIV infection in AZT-treated SCID-hu mice. Science 247:564–566
     [Google Scholar]
  20. Moore J. P. 1995; HIV vaccines,. Back to primary school [news].. Nature 376:115
     [Google Scholar]
  21. Moore J. P., McKeating J. A., Huang Y. X., Ashkenazi A., Ho D. D. 1992; Virions of primary human immunodeficiency virus type I isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp!20 retention from sCD4-sensitive isolates. Journal of Virology 66:235–243
     [Google Scholar]
  22. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III, Burton D. R., Ho O. D. 1995; Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of Virology 69:101–109
     [Google Scholar]
  23. Mosier D. E., Sieburg H. 1995; Macrophage-tropic HIV: critical for AIDS pathogenesis?. Immunology Today 15:332–339
     [Google Scholar]
  24. Mosier D. E., Gulizia R. J., Baird S. M., Wilson D. B., Spector D. H., Spector S. A. 1991; Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251:791–794
     [Google Scholar]
  25. Namikawa R., Kaneshima H., Lieberman M., Weissman I. L., McCune J. M. 1988; Infection of the SCID-hu mouse by HIV-1. Science 242:1684–1686
     [Google Scholar]
  26. Nick S., Fickenscher H., Biesinger B., Born G., Jahn G., Fleckenstein B. 1993; Herpesvirus saimiri transformed human T cell lines: a permissive system for human immunodeficiency viruses. Virology 194:875–877
     [Google Scholar]
  27. Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montroni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. 1993; HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease [see comments]. Nature 362:355–358
     [Google Scholar]
  28. Prince A. M., Reesink H., Pascual D., Horowitz B., Hewlett I., Murthy K. K., Cobb K. E., Eichberg J. W. 1991; Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Research and Human Retroviruses 7:971–973
     [Google Scholar]
  29. Reinhardt B., Torbett B. E., Gulizia R. J., Reinhardt P. P., Spector S. A., Mosier D. E. 1994; Human immunodeficiency virus type 1 infection of neonatal severe combined immunodeficient mice xenografted with human cord blood cells. AIDS Research and Human Retroviruses 10:131–141
     [Google Scholar]
  30. Safrit J. T., Fung M. S., Andrews C. A., Braun D. G., Sun W. N., Chang T. W., Koup R. A. 1993; hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp!20. AIDS 7:15–21
     [Google Scholar]
  31. Schuitemaker H., Koot M., Kootstra N. A., Dercksen M. W., de Goede R. E., Van Steenwijk R. P., Lange J. M., Schattenkerk J. K., Miedema F., Tersmette M. 1992a; Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. Journal of Virology 66:1354–1360
     [Google Scholar]
  32. Schuitemaker H., Kootstra N. A., Groenink M., de Goede R. E., Miedema F., Tersmette M. 1992b; Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. AIDS Research and Human Retroviruses 8:1679–1682
     [Google Scholar]
  33. Schuitemaker H., Groenink M., Meyaard L., Kootstra N. A., Fouchier R. A., Gruters R. A., Huisman H. G., Tersmette M., Miedema F. 1993; Early replication steps but not cell type-specific signalling of the viral long terminal repeat determine HIV-1 monocytotropism. AIDS Research and Human Retroviruses 9:669–675
     [Google Scholar]
  34. Schutten M., McKnight A., Huisman R. C., Thali M., McKeating J. A., Sodroski J., Goudsmit J., Osterhaus A. D. M. E. 1993; Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS 7:919–923
     [Google Scholar]
  35. Schutten M., Andeweg A. C., Bosch M. L., Osterhaus A. D. M. E. 1995; Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scandinavian Journal of Immunology 41:18–22
     [Google Scholar]
  36. Shih C. C., Kaneshima H., Rabin L., Namikawa R., Sager P., McGowan J., McCune J. M. 1991; Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SClD-hu mice in a time-dependent manner. Journal of Infectious Diseases 163:625–627
     [Google Scholar]
  37. Teeuwsen V. J. P., Siebelink K. H. J., Crush Stanton S., Swerdlow B., Schalken J. J., Goudsmit J., van de Akker R., Stukart M. J., UytdeHaag F. G. C. M., Osterhaus A. D. M. E. 1990; Production and characterization of a human monoclonal antibody reactive with a conserved epitope on gp41 of human immunodeficiency virus type I. AIDS Research and Human Retroviruses 6:381–392
     [Google Scholar]
  38. Tenner-Racz K., Von Stemm A. M., Guhlk B., Schmitz J., Racz P. 1994; Are follicular dendritic cells, macrophages and interdigitating cells of the lymphoid tissue productively infected by HIV?. Research in Virology 145:177–182
     [Google Scholar]
  39. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Others 1995; Viral dynamics in human immunodeficiency virus type 1 infection [see comments]. Nature 373:117–122
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-8-1667
Loading
Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model
J. Gen. Virol. 77, 1667 (1996); https://doi.org/10.1099/0022-1317-77-8-1667
/content/journal/jgv/10.1099/0022-1317-77-8-1667
/content/journal/jgv/10.1099/0022-1317-77-8-1667
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error